DOI: 10.36347/sjams.2016.v04i02.031

Pages: 469-475

Amla (Emblica officinalis) has effect on physiological and biochemical parameters of metabolic syndrome due to its anti-inflammatory, hypolipidemic, hypoglycaemic, and anti-oxidative effects. We designed a randomized controlled trial to evaluate the role of Amla therapy in glycaemic control, obesity, hypertension and managing dyslipidemia of metabolic syndrome. The method is One Hundred patients of Metabolic Syndrome were randomized to receive conventional treatment with or without Amla. The patients were evaluated for body mass index, waist hip ratio, fasting blood sugar, blood pressure, glycosylated hemoglobin and lipid profile at baseline and 3 months after starting Amla. In results we found that Amla therapy resulted in good glycemic control (both FBS and HbA1C, p<0.001); blood pressure both systolic & diastolic (p<0.001) and lipid profile (p<0.001) improved significantly in study group after Amla therapy. The parameters regarding obesity control (Body mass index and waist hip ratio) did not show significant improvement. In conclusion The Amla therapy is very efficient as an adjunct with conventional treatment (diet modification and pharmacological intervention) in management of metabolic syndrome.